Catalent, Inc.
(NYSE : CTLT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. -1.29%26.0714.1%$153.40m
AMRNAmarin Corp. Plc -2.24%17.471.7%$93.93m
CTLTCatalent, Inc. -0.15%58.712.2%$74.72m
RVMDRevolution Medicines, Inc. -2.19%30.320.0%$71.28m
GWPHGW Pharmaceuticals Plc -2.83%124.926.2%$59.38m
JAZZJazz Pharmaceuticals Plc -0.64%134.642.3%$58.51m
AXSMAxsome Therapeutics, Inc. -2.31%90.451.9%$55.17m
UTHRUnited Therapeutics Corp. -0.43%106.9614.3%$48.39m
SAGESAGE Therapeutics, Inc. -0.23%70.228.6%$43.58m
HZNPHorizon Therapeutics Plc -1.72%35.426.6%$43.24m
PRGOPerrigo Co. Plc -0.29%59.446.8%$43.20m
ZGNXZogenix, Inc. -2.98%30.009.4%$42.02m
ICPTIntercept Pharmaceuticals, Inc. 0.96%94.8116.9%$41.31m
ENDPEndo International Plc 1.47%6.208.8%$35.41m
MNKMallinckrodt Plc -1.21%5.1020.9%$34.54m

Company Profile

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.